Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference
Progenity, Inc. (Nasdaq: PROG) announced that CEO Harry Stylli will participate in a fireside chat at the virtual Raymond James 2021 Human Health Innovation Conference on June 22, 2021, at 10:40 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Progenity, Inc. (Nasdaq: PROG) announced that CEO Harry Stylli will participate in a fireside chat at the virtual Raymond James 2021 Human Health Innovation Conference on June 22, 2021, at 10:40 a.m. ET. The event will be accessible via a live webcast on the company's investor relations webpage. Progenity, a biotech company, focuses on gastrointestinal health and oral biotherapeutics, utilizing a multi-omics approach to enhance diagnostics and targeted therapies for better patient outcomes.
Details
News Market Reaction – PROG
The recorded move for PROG in the trading session of this news was -0.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Raymond James 2021 Human Health Innovation Conference at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, June 22, 2021.
A live webcast and archive of the fireside chat will be available online from the investor relations section of the company website at www.progenity.com.
About Progenity
Progenity, Inc. is a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
For more information about Progenity’s products and pipeline visit www.progenity.com, or follow the company on LinkedIn or Twitter.
Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886
Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(858) 457-2436
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.